DNA Nanobots

Executive Summary

DNA Nanobots is a Cambridge-based biotechnology company pioneering a programmable DNA nanoparticle platform for targeted therapeutic delivery. Spun out of Ohio State University in 2018, the company’s core technology uses self-assembling DNA nanostructures to encapsulate and deliver payloads—such as genes, small molecules, and proteins—specifically to diseased tissues. This approach aims to overcome key limitations of conventional therapies, including off-target toxicity and poor bioavailability, potentially transforming gene therapy, chemotherapy, and vaccine development. The company operates as both a therapeutic developer and a service provider, offering its platform to pharmaceutical partners for customized delivery solutions. As a privately held, early-stage enterprise, DNA Nanobots has not disclosed funding rounds or valuation. Its progress has been largely academic, with proof-of-concept studies expected to lead to preclinical data. The company’s dual business model positions it to generate near-term revenue through partnerships while advancing its own pipeline. However, the competitive landscape includes numerous nanoparticle delivery platforms, and regulatory hurdles remain significant. Success will depend on demonstrating in vivo efficacy, manufacturing scalability, and securing strategic collaborations to move toward clinical trials.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q4 2026Pharma Partnership for Vaccine Delivery50% success
• Q1 2027Publication of Preclinical In Vivo Data60% success